A Franco-German joint venture company – Aurobac Therapeutics – has been formed to try to tackle the rising threat of antimicrobial resistant (AMR) infections.
A consortium of life sciences companies including pharma giants such as Novartis and Johnson & Johnson, are to collaborate to develop and manufacture vaccines, diagnostics and treatment